Trimetazidine activates AMPK in diabetic myocardium.
Trimetazidine  when administered before reperfusion results in activation of p38 mitogen-activated protein kinase and Akt signaling.
Trimetazidine  when administered during reperfusion does not affect p38MAPK and JNK activation.
